相关实验视频
Updated: Jun 28, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
与代谢功能障碍相关的脂肪肝炎的新兴和新兴治疗方法
Monica A Tincopa1, Quentin M Anstee2, Rohit Loomba3
1MASLD Research Center, Division of Gastroenterology and Hepatology, University of California, San Diego, La Jolla, CA 92103, USA.
代谢功能障碍相关的脂肪肝炎 (MASH) 缺乏经批准的治疗方法,这促使人们对生活方式干预和新兴药物治疗进行审查. 本分析探讨了MASH药物开发中的挑战和解决方案,检查了临床试验中的有希望的药物.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH) 是慢性肝病的日益严重的原因,也是肝移植的主要驱动因素.
- 肥胖流行病正在推动全球MASH的发病率和流行率不断增加.
- 目前,MASH没有批准的药物治疗方法,使生活方式干预成为标准的护理.
研究的目的:
- 审查MASH药物疗法开发中的挑战和潜在解决方案.
- 概述目前正在第三阶段临床试验中的新兴MASH疗法.
- 讨论新的MASH候选药物的各种行动机制.
主要方法:
- 对当前MASH管理策略的文献综述.
- 对新兴MASH药物治疗的第三阶段临床试验数据的分析.
- 讨论药物开发中的挑战和潜在的治疗途径.
主要成果:
- 生活方式干预表明MASH管理的现实世界有效性和可持续性有限.
- 几种具有不同作用机制的新药疗法在第三阶段试验中表现出有希望的结果.
- 对MASH药物的开发环境正在迅速发展.
结论:
- 对MASH的批准药物治疗有着至关重要的未满足的需求.
- 新兴候选药物为改善MASH治疗结果提供了希望.
- 持续的研究和开发对于应对MASH流行病至关重要.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
相关概念视频
Chronic Pancreatitis II: Collaborative Care
Assessment:
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...